Member Info for JoeyDiamond

Just to add the activ-2 trial overview webinar yesterday talked about interferon still being on the trial so we not kicked off as of yesterday at least :)

The presenter also said advancement to P3 is based on a very low bar.

Activ-2 is currently recruiting around 50 ppl a day across all drugs so has slowed to a crawl. They are expanding the trial into countries like Canada and India to help boost these numbers.

The AZN mAbs progression to P3 decision is on Monday.

Yes Fauci and NIH indirectly funded the bat coronavirus GOF research at the Wuhan lab using American tax dollars. Money trails via Ecohealth are clear and have been for a very long time. There is also strong circumstantial evidence of lab leak and cover up.

This information has been known for a year already due to investigations by the DRASTIC research group. Strange only now MSM and Republicans in USA are acting on it ;/

The ‘genie’ is out the bottle for vaccines? Have you been in a time warp?

Hi Borsaci06, the report does include interferon. Quote -

Many previously analysed and once promising drugs are now proven ineffective, or even harmful. Hydroxychloroquine [5] is one such high-profile example; and despite FDA approval, remdesivir demonstrated no clinical benefit except for shorter duration of hospitalisation [6]. Furthermore, large-scale studies such as SOLIDARITY and RECOVERY have found other previously leading candidates such as lopinavir/ritonavir [6,7], interferon beta-1a [6] and azithromycin [8] to have no clinical benefit.

The reason its not included in the list of drugs is pretty obvious. WHO solidarity trial has long been a curse of interferon :)

The French Extavia trial result is due Sept/Oct by the way, the trial is still in the recruiting stage.

I don’t think there can be a Cash raise until after the 21st June meeting where holders need to vote on the resolutions first.

https://twitter.com/DavidLVBauer/status/1400580669244428289

Significant loss of antibody neutralisation vs live B.1.617.2 SARS-CoV-2 variant (-5.8x, akin to B.1.351)

Increased age & time since 2nd dose correlated with reduced virus neutralisation across all strains tested. Not a surprise, but given low starting titres vs B.1.617.2, more of a concern to see neutralisation “dropping off”, significantly. Boosters more likely to be needed.

Bit of a surprise vs B.1.617.2 as it doesnt have the E484K mutation yet still big loss of antibody neutralisation.

This is older news I shared on Reddit a few months back but is relevent to this thread.

https://www.nature.com/articles/s41392-021-00496-5

This paper suggests interferon treatment compensates for the 'bad' effects of steroids.

'Synthetic glucocorticoid dexamethasone is the first trial-proven drug that reduces COVID-19 mortality by suppressing immune system. In contrast, interferons are a crucial component of host antiviral immunity and can be directly suppressed by glucocorticoids. To investigate whether therapeutic interferons can compensate glucocorticoids-induced loss of antiviral immunity, we retrospectively analyzed a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids.' .....

With regards to secondary infections stemming from Covid-19 its a good hypothesis inhaled interferon could help in preventing them happen. In my mind there is likely a secondary benefit of SNG001 people havent picked up on yet and that is its protective effect vs these secondary infections.

For fungal infections - We are protected from fungal infections by antifungal immunity, an essential component of the interferon system (IFN).

https://interferons.info/gb/diseases/fungal-infections/interferons-and-pathogenesis-fungal-infections/#:~:text=Interferon%20activates%20the%20antifungal%20response%20of%20immune%20cells-phagocytes%2C,melanin%2C%20which%20are%20part%20of%20their%20cell%20membrane.

Something to ponder )

The slide appears in all SNG presentations as it is one of SNGs key selling points. Its also in Lancet, Activ-2 design documentation as well as Richards presentations to investors.

but yes it originates from P2 hospital trial results.

LSE have missed the other potential gold nugget in the RNS and why some are buying in

Certainly looking like this could be MAP rather than the full emergency approval. Heres hoping anyway ;)

Can anyone confirm that this is an approval or is this just for compassionate use access?

Looks like emergency approval in France given for SNG001

The amount of people getting severe disease and hospitalisation was the expected amount in the placebo arm for an outpatient trial. Other clinical trials like Regeneron for example have reported between 3% and 4% of people in placebo arm getting severe disease.

So 2 events for the SNG trial was the outpatient trial average.

Pretty interesting that the biggest group refusing the vaccine are white republicans of the Trumpian variety. I do feel refusing the vaccine for many is to try and damage Biden/Dems but this will make herd immunity more difficult.

USA vax rates are falling daily as less people take up the offer. They are now vaxxing people as young as 12.
https://ourworldindata.org/grapher/us-daily-covid-vaccine-doses-administered

46% population have had at least 1 dose
https://usafacts.org/visualizations/covid-vaccine-tracker-states/

The recent Biden get vaxxed or keep wearing a mask is a tougher stance to encourage more uptake.

Covid is incredibly political in USA now. Republicans putting in a bill to get rid of Fauci.

The FIRED Act (Fauci’s Incompetence Requires Early Dismissal Act) is scheduled to be introduced Wednesday by Rep. Warren Davidson of Ohio. Unlikely the bill will pass however as Dems control the house.

https://www.foxnews.com/politics/republican-bill-fire-fauci-biden-medical-officials-covid

Fauci is under alot of pressure in the USA as hes struggling to defend his role in indirectly funding the Wuhan lab Coronavirus gain of function research.

I disagree Mr_Big on your belief HT outpatient setting is the investment case rather than the hospital setting. Maybe this disagreement in view points and SNGs target market between investors is what caused some PI's to sell out.

Investors piled into SNG on the back of the P2 hospital results and the £87 million placing was to fund P3 hospital trial and getting the drug commercialised. For people who invested early enough this is and still is the primary reason for investing in SNG.

The excitement and the primary Covid USP for SNG is use in the early hospital setting. If you research this stage of disease there are currently very few competitors and to this day there still isn't a good drug for this stage of Covid. Drugs like mAbs, Mercks pill and Camostats pill for example have failed trials in hospital setting and are now targeting the outpatient space. This leaves SNG with a wide open commercial target.

The HT at the time was always a secondary play and using Richards words was the insurance policy. You need 1000+ patients recruited to prove efficacy in outpatients purely due to the amount of placebo events (Regeneron needed 4500 patients) something SNG would need to raise more money for if they went alone. Activ-2 inclusion was brilliant as it meant they could progress outpatient setting for free pretty much.

If you invested for hospital setting the chances of success have increased. The only negative is the P3 trial duration is now likely to over-run the original early summer timeline.

Just because you may be CEO of the year doesn't mean you are any good. I still think he needs replacing with Dido Harding.

Yes the information is correct. The other sites gave approval on 23/04.

The trial document was only updated today reflecting the changes.